[1] 成钊汀, 谭建.  分化型甲状腺癌术后患者131I治疗的辐射剂量与防护[J]. 国际放射医学核医学杂志, 2014, 38(2): 110-116.   doi: 10.3760/cma.j.issn.1673-4114.2014.02.010
Cheng ZT, Tan J.  Radiation dose and protection of differentiated thyroid carcinoma postoperative patients with 131I treatment[J]. Int J Radiat Med Nucl Med, 2014, 38(2): 110-116.   doi: 10.3760/cma.j.issn.1673-4114.2014.02.010
[2] 张英杰, 梁军, 杨雪, 等.  非远处转移性高危分化型甲状腺癌的低剂量碘-131治疗[J]. 中国医学科学院学报, 2015, 37(5): 596-601.   doi: 10.3881/j.issn.1000-503X.2015.05.018
Zhang YJ, Liang J, Yang X, et al.  Low-dose Radioiodine for Ablation in Non-metastatic High-risk Thyroid Cancer[J]. Acta Acad Med Sin, 2015, 37(5): 596-601.   doi: 10.3881/j.issn.1000-503X.2015.05.018
[3] Dehbi HM, Mallick U, Wadsley J, et al.  Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial[J]. Lancet Diabetes Endocrinol, 2019, 7(1): 44-51.   doi: 10.1016/S2213-8587(18)30306-1
[4]

中华人民共和国国家质量监督检验检疫总局, 中国国家标准化管理委员会. GB 16361-2012 临床核医学的患者防护与质量控制规范[S]. 北京: 中国标准出版社, 2012.

General Administration of Quality Supervision, Inspection and Quarantine of the People's Republic of China, Standardization Administration of China. GB 16361-2012 Specification for patient radiological protection and quality control in nuclear medicine[S]. Beijing: Standards Press of China, 2012.
[5] Egner JR.  AJCC Cancer Staging Manual[J]. JAMA, 2010, 304(15): 1726-1727.   doi: 10.1001/jama.2010.1525
[6] 谭建, 蒋宁一, 李林, 等.  131I治疗分化型甲状腺癌指南(2014版)[J]. 中华核医学与分子影像杂志, 2014, 34(4): 264-278.   doi: 10.3760/cma.j.issn.2095-2848.2014.04.002
Tan J, Jiang NY, Li L, et al.  131I guidelines for the treatment of differentiated thyroid cancer (2014)[J]. Chin J Nucl Med Mol Imaing, 2014, 34(4): 264-278.   doi: 10.3760/cma.j.issn.2095-2848.2014.04.002
[7]

中华人民共和国国家质量监督检验检疫总局. GB 18871-2002 电离辐射防护与辐射源安全基本标准[S]. 北京: 中国标准出版社, 2004.

General Administration of Quality Supervision, Inspection and Quarantine of the People's Republic of China. GB 18871-2002 Basic STANDARDs for protection against ionizing radiation and for the safety of radiation sources[S]. Beijing: Standards Press of China, 2004.
[8]

International Atomic Energy Agency. Nuclear medicine resources manual[R]. Vienna: IAEA, 2006.
[9] Martin TM, Vasudevan L, Chirayath SS.  Correlation Between Exposure Rate and Residual Activity in Felines Undergoing 131I Thyroid Ablation Therapy[J]. Health Phys, 2015, 109(2): 95-103.   doi: 10.1097/HP.0000000000000297
[10] 靳平燕, 欧阳伟, 冯会娟, 等.  131I治疗分化型甲状腺癌患者的辐射剂量率研究[J]. 广东医学, 2016, 37(3): 386-388.   doi: 10.13820/j.cnki.gdyx.2016.03.016
Jin PY, Ouyang W, Feng HJ, et al.  Study on the radiation dose rate of 131I in the treatment of differentiated thyroid cancer[J]. Guangdong Med J, 2016, 37(3): 386-388.   doi: 10.13820/j.cnki.gdyx.2016.03.016
[11] Jin PY, Feng HJ, Ouyang W, et al.  Radiation dose rates of differentiated thyroid cancer patients after 131I therapy[J]. Radiat Environ Biophys, 2018, 57(2): 169-177.   doi: 10.1007/s00411-018-0736-7
[12] Markou P, Chatzopoulos D.  Isolation Period Prediction in Patients With Differentiated Thyroid Carcinoma Treated After Thyroidectomy by Radioiodine-131[J]. Hell J Nucl Med, 2004, 7(3): 195-198.
[13] Lahfi Y, Anjak O.  Evaluation of the release criteria from hospital of thyroid carcinoma patient treated with 131I[J]. Radiat Prot Dosimetry, 2016, 171(4): 534-538.   doi: 10.1093/rpd/ncv477
[14] Asli IN, Baharfard N, Shafiei B, et al.  Relation between clinical and laboratory parameters with radiation dose rates from patients receiving iodine-131 therapy for thyroid carcinoma[J]. Radiat Prot Dosimetry, 2010, 138(4): 376-381.   doi: 10.1093/rpd/ncp269
[15] Yama N, Sakata KI, Hyodoh H, et al.  A retrospective study on the transition of radiation dose rate and iodine distribution in patients with I-131-treated well-differentiated thyroid cancer to improve bed control shorten isolation periods[J]. Ann Nucl Med, 2012, 26(5): 390-396.   doi: 10.1007/s12149-012-0586-3
[16] Demir M, Parlak Y, Çavdar I, et al.  The evaluation of urine activity and external dose rate from patients receiving radioiodine therapy for thyroid cancer[J]. Radiat Prot Dosimetry, 2013, 156(1): 25-29.   doi: 10.1093/rpd/nct036
[17] Haghighatafshar M, Banani A, Zeinali-Rafsanjani B, et al.  Impact of the Amount of Liquid Intake on the Dose Rate of Patients Treated with Radioiodine[J]. Indian J Nucl Med, 2018, 33(1): 10-13.   doi: 10.4103/ijnm.IJNM_90_17